The transition from pediatric to adult care is a challenging time for patients with neuromuscular disease and their families, as well as for providers. Increased use of disease-modifying treatments will likely lead to increased numbers of patients going through the transition process, and providers need to be aware of best practices to ensure this process is beneficial to all stakeholders. Part two of this three-part series will focus on Duchenne and other muscular dystrophies.